Dr. Degiacomi Giulia is currently a researcher in microbiology at the University of Pavia. She obtained her Bachelors degree in Biotechnology in 2006, her Masters degree in Industrial Biotechnology (Molecular Biology curriculum) in 2008 and her PhD in Genetics and Molecular Biology in 2012 at the University of Pavia. She has gained international experience as a postdoctoral fellow at Comenius University in Bratislava, Slovakia, from 2011 to 2012. In 2013, she joined the University of Padua as a postdoctoral
fellow at the Department of Molecular Medicine until 2015. Back in Pavia, she was a postdoctoral fellow at the Department of Biology and Biotechnology "L. Spallanzani" from 2018 to 2021. Since 2021, she has
been a tenure-track researcher in microbiology at the Department of Biology and Biotechnology "Lazzaro Spallanzani". Since 2020, she has been a member of the European Society for Clinical Microbiology and Infectious Diseases. Her research interests focus on tuberculosis, pre-clinical phase, drug discovery, bacterial genetics and non-tuberculous mycobacteria.
Prof. Maria Rosalia Pasca is a full professor in microbiology at the University of Pavia. She earned a Ph.D. in genetics and molecular evolution at the University of Bari, Italy, in 2002. She was a post-doc researcher from April 2002 to September 2006. She was a researcher in microbiology from October 2006 to February 2015 at the University of Pavia. She has been an associate professor in microbiology from March 2015 to March 2021. Since March 2021, she has been a full professor. She is a partner in the project “Deciphering host-pathogen interactions to eradicate intracellular mycobacteria pathogens: key drivers to design new precision nanomedicine tools” funded by PRIN 2020. She is the Head of UNIPV Unit in the Project “ERA4TB” funded by EC. She was the principal investigator in three projects (new weapons against Mycobacterium abscessus and other nontuberculous mycobacteria) funded by the Fondazione Italiana Ricerca Fibrosi Cistica. Her main research activities are (1) searching for new antitubercular drugs and novel targets and (2) developing new weapons against Mycobacterium abscessus and other nontuberculous Mycobacteria.
